The response to a severe burn is characterized by persistent hypermetabolic and catabolic state that result in the massive loss of muscle tissue, even in the fed state. In patients with >30% of total body surface area burned, protein breakdown persists for approximately one year after the burn wound is 95% healed. Endogenous catecholamines have been implicated as primary mediators of the hypermetabolic response to trauma or burn. Chronic elevation of plasma catecholamine levels results in the development of hyperdynamic circulation, increased basal energy expenditure, peripheral insulin resistance with hyperglycemia, increased peripheral lipolysis, depressed immune function, skeletal muscle protein catabolism and hypertrophic scarring. The hypermetabolic response to burns is also characterized by a profound tachycardia and increased cardiac work that are detrimental to the heart. The persistence of tachycardia and muscle catabolism significantly compromises rehabilitation and results in an excessive delay before resuming normal physical and functional activities. Recent studies from our institution have shown the negative impact of hyperglycemia and insulin resistance on survival, wound healing, and skeletal muscle catabolism. Insulin resistance can last for at least 3 years in severely burned patients, further delaying a patient's return to normal and reducing their quality of life. In the previous funding period, we demonstrated that administration of intensive insulin alone or in combination with propranolol improves outcomes for severely burned patients. However, the use of insulin was associated with high levels of hypoglycemia. Therefore, we now will utilize an anti-hyperglycemic therapy that does not have the risk of hypoglycemia. We have shown that acute administration of fenofibrate, a fibrate, reduces blood glucose levels in severely burned patients. We will now administer fenofibrate alone or in combination with propranolol to determine the clinical efficacy and underlying mechanisms of action on insulin resistance, wound healing, sepsis, and cardiac function. We hypothesize that reduction of blood glucose levels, along with blockade of catecholamines, will result in attenuation of the long-term post-burn catabolic and hypermetabolic responses, and that these responses will be ameliorated by the therapeutic use of fenofibrate alone or in combination with propranolol, administered for one year post burn. A total of 300 patients will be randomized to receive daily administration of Fenofibrate alone or in combination with propranolol. Comparison of the data from these patients to an equal number of placebo- or propranolol-treated patients will be accomplished using data from our already funded P50 burn center trial which will be completed by January 2015.

Public Health Relevance

Severely burned patients experience long-term insulin resistance and increased cardiac work that can last for year's post- injury, increasing long-term morbidity. This will be the first trial of year-long administration of fenofibrate alone or in combination with propranolol. This long-term clinical trial will advance the understanding of burn-induced tissue-specific signaling pathways, alterations in clinical indices such as insulin resistance, body composition, and scarring, and may improve clinical outcomes of burn patients, and by extension also improve these in other hypermetabolic and hypercatabolic states.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM056687-14
Application #
8629361
Study Section
Special Emphasis Panel (ZRG1-SBIB-V (82))
Program Officer
Somers, Scott D
Project Start
1998-01-01
Project End
2018-04-30
Budget Start
2014-08-05
Budget End
2015-04-30
Support Year
14
Fiscal Year
2014
Total Cost
$1,102,701
Indirect Cost
$382,701
Name
University of Texas Medical Br Galveston
Department
Surgery
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Cambiaso-Daniel, Janos; Malagaris, Ioannis; Rivas, Eric et al. (2017) Body Composition Changes in Severely Burned Children During ICU Hospitalization. Pediatr Crit Care Med 18:e598-e605
Prasai, Anesh; El Ayadi, Amina; Mifflin, Randy C et al. (2017) Characterization of Adipose-Derived Stem Cells Following Burn Injury. Stem Cell Rev 13:781-792
Bohanon, Fredrick J; Lopez, Omar Nunez; Herndon, David N et al. (2017) Burn Trauma Acutely Increases the Respiratory Capacity and Function of Liver Mitochondria. Shock :
Wurzer, Paul; Forbes, Abigail A; Hundeshagen, Gabriel et al. (2017) Two-year follow-up of outcomes related to scarring and distress in children with severe burns. Disabil Rehabil 39:1639-1643
Foncerrada, Guillermo; Lima, Francisco; Clayton, Robert P et al. (2017) Safety of Nebulized Epinephrine in Smoke Inhalation Injury. J Burn Care Res 38:396-402
Guillory, Ashley N; Herndon, David N; Silva 3rd, Michael B et al. (2017) Oxandrolone Coadministration Does Not Alter Plasma Propranolol Concentrations in Severely Burned Pediatric Patients. J Burn Care Res 38:243-250
Hundeshagen, Gabriel; Wurzer, Paul; Forbes, Abigail A et al. (2017) The occurrence of single and multiple organ dysfunction in pediatric electrical versus other thermal burns. J Trauma Acute Care Surg 82:946-951
Hundeshagen, Gabriel; Collins, Vanessa N; Wurzer, Paul et al. (2017) A Prospective, Randomized, Controlled Trial Comparing the Outpatient Treatment of Pediatric and Adult Partial-Thickness Burns with Suprathel or Mepilex Ag. J Burn Care Res :
Clayton, Robert P; Wurzer, Paul; Andersen, Clark R et al. (2017) Effects of different duration exercise programs in children with severe burns. Burns 43:796-803
Wurzer, Paul; Cole, Megan R; Clayton, Robert P et al. (2017) Herpesviradae infections in severely burned children. Burns 43:987-992

Showing the most recent 10 out of 166 publications